PAR 2 expression in peripheral blood monocytes of patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 71, Issue 6, 2012, Pages 1049-1054

  Crilly, A ^a   Burns, E ^a   Nickdel, M B ^a   Lockhart, J C ^a   Perry, M E ^b   Ferrell, P W ^c   Baxter, D ^d   Dale, J ^e   Dunning, L ^a   Wilson, H ^f   Nijjar, J S ^e   Gracie, J A ^e   Ferrell, W R ^e   McInnes, I B ^e  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^b ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^c WESTERN INFIRMARY   (United Kingdom)

^d SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f STOBHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; INTERLEUKIN 6; METHOTREXATE; PROTEINASE ACTIVATED RECEPTOR 2; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CELL LEVEL; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; OSTEOARTHRITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; T LYMPHOCYTE SUBPOPULATION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD14; ANTIGENS, CD3; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MONOCYTES; OSTEOARTHRITIS; RECEPTOR, PAR-2;

EID: 84860915570     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-200703     Document Type: Article

References (25)

1. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82. (Pubitemid 32476117)
2. Shpacovitch V, Feld M, Hollenberg MD, et al. Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol 2008;83:1309-22. (Pubitemid 351960309)
3. Ferrell WR, Lockhart JC, Kelso EB, et al. Essential role for proteinase-activated receptor-2 in arthritis. J. Clin Invest 2003;111:35-41. (Pubitemid 36134846)
4. Shpacovitch VM, Brzoska T, Buddenkotte J, et al. Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor kappaB in human dermal microvascular endothelial cells. J Invest Dermatol 2002;118:380-5. (Pubitemid 34158497)
5. Kelso EB, Ferrell WR, Lockhart JC, et al. Expression and proinflammatory role of proteinase-activated receptor 2 in rheumatoid synovium: ex vivo studies using a novel proteinase-activated receptor 2 antagonist. Arthritis Rheum 2007;56:765-71. (Pubitemid 46399423)
6. Busso N, Frasnelli M, Feifel R, et al. Evaluation of protease-activated receptor 2 in murine models of arthritis. Arthritis Rheum 2007;56:101-7. (Pubitemid 46106182)
7. Johansson U, Lawson C, Dabare M, et al. Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-1{beta}. J Leukoc Biol 2005;78:967-75. (Pubitemid 41384413)
8. Colognato R, Slupsky JR, Jendrach M, et al. Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells. Blood 2003;102:2645-52. (Pubitemid 37193608)
9. Fields RC, Schoenecker JG, Hart JP, et al. Protease-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol 2003;162:1817-22. (Pubitemid 36613040)
10. Bingham CO 3rd, Pohl C, Woodworth TG, et al. Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group). J Rheumatol 2009;36:2335-41.
11. Kanke T, Macfarlane SR, Seatter MJ, et al. Proteinase-activated receptor-2-mediated activation of stress-activated protein kinases and inhibitory kappa B kinases in NCTC 2544 keratinocytes. J Biol Chem 2001;276:31657-66.
12. Goh FG, Ng PY, Nilsson M, et al. Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling. Br J Pharmacol 2009;158:1695-704.
13. Shpacovitch VM, Seeliger S, Huber-Lang M, et al. Agonists of proteinase-activated receptor-2 affect transendothelial migration and apoptosis of human neutrophils. Exp Dermatol 2007;16:799-806. (Pubitemid 47377644)
14. Häupl T, Østensen M, Grützkau A, et al. Interaction between rheumatoid arthritis and pregnancy: correlation of molecular data with clinical disease activity measures. Rheumatology 2008;47(Suppl 3):iii19-22.
15. Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1125-32.
16. Roosterman D, Schmidlin F, Bunnett NW. Rab5a and rab11a mediate agonist-induced trafficking of protease-activated receptor 2. Am J Physiol Cell Physiol 2003;284:C1319-29. (Pubitemid 36457413)
17. Déry O, Thoma MS, Wong H, et al. Trafficking of proteinase-activated receptor-2 and beta-arrestin-1 tagged with green fluorescent protein. beta-Arrestin-dependent endocytosis of a proteinase receptor. J Biol Chem 1999;274:18524-35.
18. Hasdemir B, Murphy JE, Cottrell GS, et al. Endosomal deubiquitinating enzymes control ubiquitination and down-regulation of protease-activated receptor 2. J Biol Chem 2009;284:28453-66.
19. Ritchie E, Saka M, Mackenzie C, et al. Cytokine upregulation of proteinase-activated-receptors 2 and 4 expression mediated by p38 MAP kinase and inhibitory kappa B kinase beta in human endothelial cells. Br J Pharmacol 2007;150:1044-54. (Pubitemid 46625087)
20. Espersen GT, Vestergaard M, Ernst E, et al. Tumour necrosis factor alpha and interleukin-2 in plasma from rheumatoid arthritis patients in relation to disease activity. Clin Rheumatol 1991;10:374-6.
21. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001;44:1237-47. (Pubitemid 32537520)
22. Tindell AG, Kelso EB, Ferrell WR, et al. Correlation of protease-activated receptor-2 expression and synovitis in rheumatoid and osteoarthritis. Rheumatol Int 2011 Sep 13 [Epub ahead of print].
23. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum 2010;62:869-77.
24. Fonseca JE, Santos MJ, Canhão H, et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538-42.
25. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.